GleamWall
中文EN

ASND Ascendis Pharma A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY98.0%
TTM net income YoY39.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR141.4%
Net income 3-yr CAGR—

Margins

Gross margin86.8%
Operating margin-18.9%
Net margin-31.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-18.4%
ROIC (approx.)-111.1%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets112.5%
Debt / equity—
Current ratio1.04x
Interest coverage-1.69x

Cash quality & payout

Operating cash flow / net income-0.24x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue720.13M363.64M
Cost of revenue94.92M44.26M
Gross profit625.22M319.38M
R&D expense303.62M307.00M
SG&A expense457.87M291.14M
Operating income-136.27M-278.76M
Interest expense80.65M65.50M
Pretax income-212.65M-373.24M
Income tax15.38M4.84M
Net income-228.03M-378.08M
EPS (basic)-3.76-6.53
EPS (diluted)-3.76-6.53
Balance sheet
Cash & equivalents616.04M559.54M
Receivables141.33M166.28M
Inventory301.53M295.61M
Current assets1.11B1.06B
PP&E, netmay include right-of-use assets (IFRS)146.48M98.71M
Total assets1.30B1.18B
Current liabilities1.07B907.86M
Short-term debt429.39M458.21M
Long-term debt385.25M365.08M
Total debt814.64M823.29M
Total liabilities1.47B1.29B
Shareholders' equity-162.82M-105.71M
Net debt198.60M263.74M
Cash flow statement
Operating cash flow53.90M-306.20M
Investing cash flow-8.48M6.88M
Financing cash flow36.33M443.93M
Stock-based compensation116.17M95.51M
Share buybacks17.40M0

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.